Latest news

Debiopharm and Vifor Pharma sign an exclusive agreement for the distribution and commercialization of Pamorelin® LA in Switzerland – A…

Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent…

Ipsen and Debiopharm Group announce that Decapeptyl® (triptorelin embonate) 6-month successfully completes the European Decentralised Procedure for the treatment of…

Debiopharm and Mepha sign distribution agreement for Pamorelin® LA 1-3- and 6-month formulations – a new treatment for prostate cancer…

Bachem and Debiopharm sign follow-up contract for long-term supply of Triptorelin Pamoate

Debiopharm announces U.S. NDA filing of Trelstar® 6-month formulation for locally advanced or metastatic prostate cancer

Debiopharm moves towards a new 6-month formulation of Decapeptyl® to further help prostate cancer patients

Clinical Update – Decapeptyl®/Trelstar® 6-Month Formulation in Advanced Prostate Cancer

Ipsen and Debiopharm extend their Agreement for the Exclusive Commercialization of Decapeptyl®